Study summary

The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).

Additional Study Details

Phase
Phase 4
Product
  • Enzalutamide
  • Flutamide
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    206
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): Japanese
    Protocol
    Available Language(s): English
    Statistical Analysis Plan (SAP)
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for Study on Enzalutamide and Flutamide in Patients with Castration Resistant Prostate Cancer? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP00032
      Osaka, Osaka, Japan
      Completed
      Site JP00022
      Hamamatsu, Shizuoka, Japan
      Completed
      Site JP00048
      Sapporo, Hokkaido, Japan
      Completed
      Site JP00031
      Osaka, Osaka, Japan
      Completed
      Site JP00044
      Yokosuka, Kanagawa, Japan
      Completed
      Site JP00030
      Osakasayama, Osaka, Japan
      Completed
      Site JP00050
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00001
      Sapporo, Hokkaido, Japan
      Completed
      Site JP00028
      Hirakata, Osaka, Japan
      Completed
      Site JP00038
      Matsuyama, Ehime, Japan
      Completed
      Site JP00040
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00025
      Nagoya, Aichi, Japan
      Completed
      Site JP00043
      Ota, Gunma, Japan
      Completed
      Site JP00017
      Bunkyo-ku, Tokyo, Japan
      Completed
      Site JP00020
      Yokohama, Kanagawa, Japan
      Completed
      Site JP00035
      Hiroshima, Hiroshima, Japan
      Completed
      Site JP00019
      Sagamihara, Kanagawa, Japan
      Completed
      Site JP00052
      Toyama, Toyama, Japan
      Completed
      Site JP00055
      Mito, Ibaraki, Japan
      Completed
      Site JP00002
      Sapporo, Hokkaido, Japan
      Completed
      Site JP00021
      Yokohama, Kanagawa, Japan
      Completed
      Site JP00010
      Chiba, Chiba, Japan
      Completed
      Site JP00039
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00034
      Ube, Yamaguchi, Japan
      Completed
      Site JP00049
      Utsunomiya, Tochigi, Japan
      Completed
      Site JP00016
      Shinagawa-ku, Tokyo, Japan
      Completed
      Site JP00011
      Bunkyo-ku, Tokyo, Japan
      Completed
      Site JP00013
      Koto-ku, Tokyo, Japan
      Completed
      Site JP00046
      Kashihara, Nara, Japan
      Completed
      Site JP00054
      Hakodate, Hokkaido, Japan
      Completed
      Site JP00027
      Suita, Osaka, Japan
      Completed
      Site JP00024
      Nagoya, Aichi, Japan
      Completed
      Site JP00053
      Chiba, Chiba, Japan
      Completed
      Site JP00006
      Nagano, Nagano, Japan
      Completed
      Site JP00026
      Kyoto, Kyoto, Japan
      Completed
      Site JP00014
      Nakano-ku, Tokyo, Japan
      Completed
      Site JP00005
      Maebashi, Gunma, Japan
      Completed
      Site JP00033
      Kurashiki, Okayama, Japan
      Completed
      Site JP00018
      Shinjuku-ku, Tokyo, Japan
      Completed
      Site JP00045
      Isesaki, Gunma, Japan
      Completed
      Site JP00029
      Osaka, Osaka, Japan
      Completed
      Site JP00008
      Nagano, Nagano, Japan
      Completed
      Site JP00009
      Kitaadachi-gun, Saitama, Japan
      Completed
      Site JP00051
      Iizuka, Fukuoka, Japan
      Completed
      Site JP00041
      Nagasaki, Nagasaki, Japan
      Completed
      Site JP00037
      Tokushima, Tokushima, Japan
      Completed
      Site JP00042
      Saga, Saga, Japan

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?